Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that James Caruso, president and CEO, will present an overview of the company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be held virtually on February 14, 2024, at 2:00 – 2:30 pm Eastern Time. A webcast will be available, and a replay can be accessed on the company's investor relations website.

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34^th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:

Date:		Wednesday, February 14, 2024
Time:		2:00 – 2:30 pm Eastern Time
Webcast:		Click HERE

A replay of the presentation will be available on Events section of the company’s investor relations website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com

INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com

FAQ

When is the Oppenheimer 34th Annual Healthcare Life Sciences Conference presentation for Cellectar Biosciences, Inc.?

The presentation is scheduled for Wednesday, February 14, 2024, at 2:00 – 2:30 pm Eastern Time.

Where can I watch the webcast of the presentation?

The webcast can be accessed by clicking on the provided link.

Will there be a replay of the presentation available?

Yes, a replay of the presentation will be available on the Events section of the company’s investor relations website.